Acute megakaryoblastic leukemia pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(7 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Acute megakaryoblastic leukemia}}
{{Acute megakaryoblastic leukemia}}
{{CMG}}
{{CMG}}; {{AE}}
 
==Overview==
==Overview==
==Pathophysiology==
==Pathophysiology==
It is associated with [[GATA1]], and risks are increased in individuals with [[Down syndrome]].<ref name="pmid12586620">{{cite journal |author=Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A |title=GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome |journal=Blood |volume=101 |issue=11 |pages=4301–4 |year=2003 |pmid=12586620 |doi=10.1182/blood-2003-01-0013 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=12586620}}</ref> However, not all cases are associated with Down syndrome,<ref name="pmid18275433">{{cite journal |author=Hama A, Yagasaki H, Takahashi Y, ''et al'' |title=Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome |journal=Br. J. Haematol. |volume=140 |issue=5 |pages=552–61 |year=2008 |pmid=18275433 |doi=10.1111/j.1365-2141.2007.06971.x |url=http://dx.doi.org/10.1111/j.1365-2141.2007.06971.x}}</ref> and other genes can also be associated with AMKL.<ref name="pmid17360941">{{cite journal |author=Gu TL, Mercher T, Tyner JW, ''et al'' |title=A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia |journal=Blood |volume=110 |issue=1 |pages=323–33 |year=2007 |pmid=17360941 |doi=10.1182/blood-2006-10-052282 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=17360941}}</ref>


This category of AML is associate with 30% or more blasts in the marrow, blast are identified as being of megakaryocyte lineage by; Expression of [[megakaryocyte]] specific [[antigen]]s and platelet [[peroxidase]] reaction on electron microscopy.
*It is associated with [[GATA1]], and risks are increased in individuals with [[Down syndrome]].<ref name="pmid12586620">{{cite journal |author=Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A |title=GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome |journal=Blood |volume=101 |issue=11 |pages=4301–4 |year=2003 |pmid=12586620 |doi=10.1182/blood-2003-01-0013 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=12586620}}</ref> However, not all cases are associated with Down syndrome,<ref name="pmid18275433">{{cite journal |author=Hama A, Yagasaki H, Takahashi Y, ''et al'' |title=Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome |journal=Br. J. Haematol. |volume=140 |issue=5 |pages=552–61 |year=2008 |pmid=18275433 |doi=10.1111/j.1365-2141.2007.06971.x |url=http://dx.doi.org/10.1111/j.1365-2141.2007.06971.x}}</ref> and other [[genes]] can also be associated with AMKL.<ref name="pmid17360941">{{cite journal |author=Gu TL, Mercher T, Tyner JW, ''et al'' |title=A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia |journal=Blood |volume=110 |issue=1 |pages=323–33 |year=2007 |pmid=17360941 |doi=10.1182/blood-2006-10-052282 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=17360941}}</ref>
 
*According to the report of the [[French-American-British]] Cooperative Group, this category of AML (M7 subtype) is associated with 30% or more blasts in the bone marrow. Blasts are identified as being of megakaryocyte lineage by; expression of [[megakaryocyte]] specific [[antigen]]s and platelet [[peroxidase]] reaction on [[electron microscopy]].<ref name="Bennett19852">{{cite journal|last1=Bennett|first1=John M.|title=Criteria for the Diagnosis of Acute Leukemia of Megakaryocyte Lineage (M7)|journal=Annals of Internal Medicine|volume=103|issue=3|year=1985|pages=460|issn=0003-4819|doi=10.7326/0003-4819-103-3-460}}</ref>
 
*[[Myelofibrosis]] is usually associated with AMKL; however, the exact underlying pathophysiology is controversial. The investigators did not find any direct correlation between acute myelofibrosis and the [[fibroblasts]] obtained from the bone marrow of patients with AMKL. Nevertheless, it was proposed that some humoral factors may play a key role in developing bone marrow fibrosis.<ref name="ClareElson1982">{{cite journal|last1=Clare|first1=Nanette|last2=Elson|first2=David|last3=Manhoff|first3=Louis|title=Cytogenetic Studies of Peripheral Myeloblasts and Bone Marrow Fibroblasts in Acute Myelofibrosis|journal=American Journal of Clinical Pathology|volume=77|issue=6|year=1982|pages=762–766|issn=0002-9173|doi=10.1093/ajcp/77.6.762}}</ref>
 
*[[Transforming Growth Factor-β]] (TG-β) was identified to be the significant contributor in AMKL associated myelofibrosis in addition to some other unknown factors due to the strong stimulatory effects on [[collagen]].<ref name="TeruiNiitsu1990">{{cite journal|last1=Terui|first1=T|last2=Niitsu|first2=Y|last3=Mahara|first3=K|last4=Fujisaki|first4=Y|last5=Urushizaki|first5=Y|last6=Mogi|first6=Y|last7=Kohgo|first7=Y|last8=Watanabe|first8=N|last9=Ogura|first9=M|last10=Saito|first10=H|title=The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis|journal=Blood|volume=75|issue=7|year=1990|pages=1540–1548|issn=0006-4971|doi=10.1182/blood.V75.7.1540.1540}}</ref>
 
 
<br />


==References==
==References==

Latest revision as of 14:08, 26 April 2021

Acute megakaryoblastic leukemia Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute megakaryoblastic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute megakaryoblastic leukemia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute megakaryoblastic leukemia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute megakaryoblastic leukemia pathophysiology

CDC on Acute megakaryoblastic leukemia pathophysiology

Acute megakaryoblastic leukemia pathophysiology in the news

Blogs on Acute megakaryoblastic leukemia pathophysiology

Directions to Hospitals Treating Acute megakaryoblastic leukemia

Risk calculators and risk factors for Acute megakaryoblastic leukemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Pathophysiology

  • It is associated with GATA1, and risks are increased in individuals with Down syndrome.[1] However, not all cases are associated with Down syndrome,[2] and other genes can also be associated with AMKL.[3]
  • Myelofibrosis is usually associated with AMKL; however, the exact underlying pathophysiology is controversial. The investigators did not find any direct correlation between acute myelofibrosis and the fibroblasts obtained from the bone marrow of patients with AMKL. Nevertheless, it was proposed that some humoral factors may play a key role in developing bone marrow fibrosis.[5]
  • Transforming Growth Factor-β (TG-β) was identified to be the significant contributor in AMKL associated myelofibrosis in addition to some other unknown factors due to the strong stimulatory effects on collagen.[6]



References

  1. Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A (2003). "GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome". Blood. 101 (11): 4301–4. doi:10.1182/blood-2003-01-0013. PMID 12586620.
  2. Hama A, Yagasaki H, Takahashi Y; et al. (2008). "Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome". Br. J. Haematol. 140 (5): 552–61. doi:10.1111/j.1365-2141.2007.06971.x. PMID 18275433.
  3. Gu TL, Mercher T, Tyner JW; et al. (2007). "A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia". Blood. 110 (1): 323–33. doi:10.1182/blood-2006-10-052282. PMID 17360941.
  4. Bennett, John M. (1985). "Criteria for the Diagnosis of Acute Leukemia of Megakaryocyte Lineage (M7)". Annals of Internal Medicine. 103 (3): 460. doi:10.7326/0003-4819-103-3-460. ISSN 0003-4819.
  5. Clare, Nanette; Elson, David; Manhoff, Louis (1982). "Cytogenetic Studies of Peripheral Myeloblasts and Bone Marrow Fibroblasts in Acute Myelofibrosis". American Journal of Clinical Pathology. 77 (6): 762–766. doi:10.1093/ajcp/77.6.762. ISSN 0002-9173.
  6. Terui, T; Niitsu, Y; Mahara, K; Fujisaki, Y; Urushizaki, Y; Mogi, Y; Kohgo, Y; Watanabe, N; Ogura, M; Saito, H (1990). "The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis". Blood. 75 (7): 1540–1548. doi:10.1182/blood.V75.7.1540.1540. ISSN 0006-4971.

Template:WH Template:WS